Compounds > lenalidomide
Page last updated: 2024-09-05

lenalidomide and Delayed Hypersensitivity

lenalidomide has been researched along with Delayed Hypersensitivity in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Aumann, S; Gatt, ME; Lebel, E; Parnasa, E; Ribak, Y; Rubin, L; Saban, R; Shamriz, O; Tal, Y; Talmon, A; Vainstein, V1
Ballesteros, M; Noguerado-Mellado, B; Rojas-Pérez-Ezquerra, PD; Tornero Molina, P; Zubeldia Ortuño, JM1
Cabañas, R; Castellar PharmG, FR; Dominguez-Ortega, J; Fiandor, A; Gonzalez-Muñoz, M; Heredia, R; Lazzarato, I; López de la Guía, A1
Bahlis, NJ; Bailey, K; Duggan, P; Jimenez-Zepeda, VH; McCulloch, S; Neri, P; Tay, J; Yau, P1
Castells, M; Fanning, L; Laubach, J; Lee, MJ; Richardson, P; Schlossman, R; Wickner, P1

Other Studies

5 other study(ies) available for lenalidomide and Delayed Hypersensitivity

ArticleYear
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
    European journal of haematology, 2023, Volume: 110, Issue:4

    Topics: Exanthema; Humans; Hypersensitivity, Delayed; Lenalidomide; Multiple Myeloma; Retrospective Studies

2023
Delayed Hypersensitivity Reaction to Lenalidomide: 2 Different Clinical Patterns in the Same Patient.
    Journal of investigational allergology & clinical immunology, 2019, Volume: 29, Issue:4

    Topics: Aged; Drug Hypersensitivity; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Phenotype; Skin Tests

2019
Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT.
    European annals of allergy and clinical immunology, 2020, Volume: 52, Issue:5

    Topics: Aged; Allergens; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Hypersensitivity, Delayed; Immunologic Tests; Lenalidomide; Lymphocyte Activation; Male; T-Lymphocytes; Treatment Outcome

2020
Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
    Leukemia & lymphoma, 2019, Volume: 60, Issue:13

    Topics: Aged; Aged, 80 and over; Cancer Care Facilities; Desensitization, Immunologic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Exanthema; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Outpatient Clinics, Hospital; Skin; Time Factors; Treatment Outcome

2019
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
    British journal of haematology, 2014, Volume: 167, Issue:1

    Topics: Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome

2014